NCT06843967 2026-03-13
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
Memorial Sloan Kettering Cancer Center
USWM, LLC (dba US WorldMeds)
Mario Negri Institute for Pharmacological Research